News
ATHE
2.200
+4.76%
0.100
Weekly Report: what happened at ATHE last week (1209-1213)?
Weekly Report · 5d ago
Alterity Therapeutics Price Target Announced at $8.00/Share by Maxim Group
Dow Jones · 12/12 16:53
Maxim Group Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $8
Benzinga · 12/12 16:43
Alterity Therapeutics initiated with a Buy at Maxim
TipRanks · 12/12 12:40
Weekly Report: what happened at ATHE last week (1202-1206)?
Weekly Report · 12/09 11:23
Alterity Therapeutics completes last patient visit in ATH434-201 trial
TipRanks · 12/04 12:40
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Barchart · 12/04 06:35
Weekly Report: what happened at ATHE last week (1125-1129)?
Weekly Report · 12/02 11:23
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 11/29 21:06
Weekly Report: what happened at ATHE last week (1118-1122)?
Weekly Report · 11/25 11:15
Alterity Therapeutics appoints Abby Macnish Niven as secretary
TipRanks · 11/19 12:30
Weekly Report: what happened at ATHE last week (1111-1115)?
Weekly Report · 11/18 11:12
Alterity Therapeutics announces presentation on bioMUSE study
TipRanks · 11/12 13:30
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
Barchart · 11/12 06:35
Weekly Report: what happened at ATHE last week (1104-1108)?
Weekly Report · 11/11 11:25
Alterity Therapeutics announces new publication on ATH434
TipRanks · 11/06 12:55
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
Barchart · 11/06 06:35
Weekly Report: what happened at ATHE last week (1028-1101)?
Weekly Report · 11/04 11:22
Alterity Therapeutics reports cash balance of A$9.28M as of September 30
TipRanks · 10/31 11:47
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
Barchart · 10/31 06:35
More
Webull provides a variety of real-time ATHE stock news. You can receive the latest news about Alterity Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ATHE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.